Call for application: Course on Translational Research and Medicine Development

TMex@Berlin 2023 – Translational Medicine explained
Bayer Pharmaceuticals Headquarters, Berlin – 13-17 November 2023

Target audience

PhD/MD students in the second half of their PhD, postdocs and other young cientists involved in biomedical research.

About the course

The TMex course

 Provides a birds eye view of the medicine discovery & development process
 Raises awareness of obstacles and challenges involved
 Introduces the different players (academia, SME, pharma, regulatory) and career options

Registration (now open)

First come, first serve. There are only 30 seats, so we recommend applying early. The registration will close
when all seats are filled.

Costs

The course fee is 650€.
A special discounted fee of 500€ applies for EATRIS members, Enlight-ten+ & I2TRON students.
A special discounted fee of 250€ applies for EUPATI fellows, participants coming from EU-13 countries,
Africa and Latin America.
To encourage more sustainable travel, a special “green discount” of 75€ will be refunded to participants
coming by train from further than 500km.

What our students say

• “If you have the opportunity to take part in this course – do it. It will fundamentally change your view on how
your work as a research scientist can make a difference in the real world outside your lab” (Konstantin Kuhne)
• “Very interactive course with a non-traditional approach. The course reflects the reality of translational
medicine: getting a lot of people with different backgrounds to work together as a team” (Miriam Ayuso)
• “It was a difficult decision to leave the lab for 5 days but it is absolutely worth it” (Kevin Ferreira)
• “This course taught me things I didn’t know would even exist. The course inspired me that the PhD is more than
just gaining scientific knowledge, but also to use the time to work on my personality” (Inga Hensel)

Confirmed speakers

Jenny Fitting, Head of AAV and Protein Science at Bayer
Robert Harris, Professor of Immunotherapy in Neurological Diseases at Karolinska Institutet
Thomas Steger-Hartmann, Head of Investigational Toxicology at Bayer
Piret Baur, Communications manager at EATRIS
Marc Kunze, Senior Project Lead Toxicology at Bayer
Keith Williams, retired Director at KW Drug Developments
Anke Schulte, Head of Cell & Gene Therapy Research & Preclinical Development at Bayer
Mike Hardman, retired VP IMI Collaborations at AstraZeneca
Jörg Lippert, Head Pharmacometrics at Bayer
Özlem Vural, Expert in Microphysiological Systems at Bayer
Stefan Bracht, VP Drug Delivery Innovation at Bayer

Find out more